Many investigational new drug (IND) applications fail during preclinical and clinical development due to the drug’s poor pharmacokinetic properties and toxicity, which result in a high attrition rate.
Early in vitro ADME studies, in parallel with approaches for optimizing the biochemical and cellular activities of the compounds, ensure that only the most promising compound is selected as your lead candidate.
Our strong focus on lab operations, automation, and project management enables efficient delivery and unparalleled quality.
Our team uses optimized in vitro testing systems (e.g., hepatocytes, liver microsomes) and access to analytical instruments such as high-throughput tandem mass spectrometry LC/MS/MS systems and robotic automation systems.
Explore ADMET Services at Frontage
Metabolic Stability
Predicting clearance and estimating bioavailability
CYP Interaction
Frontage is a reliable provider of early-stage screening services for drug-drug interactions (DDI)
Permeability & Transporters
Insights into compound permeability and interactions
Physicochemical Properties
Uncovering key properties of your compounds
Protein Binding
Revealing true drug availability
Metabolite Identification
Offering rapid metabolite profiling
Discovery PK & Toxicology
Strengthening regulatory readiness with timely early-stage studies
Resources To Consider
Global Drug Discovery Services Overview
In Vitro ADME Services
